ATAI (AtaiBeckley) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATAI AtaiBeckley Inc ATAI
56 GF Score
Price $7.08
GF Value $6.89
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is AtaiBeckley Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

ATAI
56GF Score
AtaiBeckley Inc ATAI
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AtaiBeckley (ATAI) Overvalued in 2026?

Based on GuruFocus' analysis, AtaiBeckley stock appears to be overvalued. The current stock price of $7.08 is trading 2.7% above its estimated GF Value™ of $6.89. GuruFocus considers AtaiBeckley to be Fairly Valued.

Key valuation signals for ATAI:

  • Dividends Received:
  • GF Value™: $6.89 vs. price of $7.08 (2.7% above fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the ATAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AtaiBeckley Business Description

Other Exchanges B72:Germany
Address 250 West 34th Street, New York, NY, USA, 10119
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
56GF Score

Get the complete analysis for ATAI

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.08
Price
$6.89
GF Value